Author:
Horowitz Diane Lewis,Furie Richard
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.
2. •• Wallace DJ, Stohl W, Furie RA, Lisse JR McKay JD, et al. A phase II, randomized, double-blind, placebo controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61(9):1168–1178. These are the published results of a phase 2 trial for belimumab in SLE.
3. •• Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet 2011; 377(9767): 721–731. These are the published results of a phase 3 trial for belimumab in SLE.
4. •• Furie RA, Petri M, Zamani O, Cervera R, Wallace DJ. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63(12): 3918–3930. These are the published results of a phase 3 trial for belimumab in SLE.
5. • FDA. Guidance for Industry Systemic Lupus Erythematosus-Developing Medical Products for Treatment. June 2010. Found at http://wwjhw.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf (accessed 2/8/2012). These are the FDA recommendations for SLE trial design.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献